Physician profile
Robert Dewberry
NPI 1922194380
$3,548.51
in general payments reported to CMS, 2019-2025
17 companies · $801 in 2025
The $801 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.74 · 2021: $37.98 · 2022: $796 · 2023: $1,055 · 2024: $818 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $569.20 | 2021-2025 | Vyepti |
| Abbvie INC. | $489.20 | 2021-2025 | Qulipta, Ubrelvy |
| Emd Serono, INC. | $459.12 | 2022-2025 | Mavenclad |
| Glaxosmithkline, LLC. | $343.20 | 2023-2024 | Arexvy |
| Dexcom, INC. | $279.05 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $277.52 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $196.34 | 2022 | |
| Abbott Laboratories | $166.25 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $161.28 | 2022-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $157.76 | 2024-2025 | Tezspire, Farxiga |
| Ucb, INC. | $155.15 | 2022-2024 | Nayzilam, Briviact |
| Sumitomo Pharma America, INC. | $110.00 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $70.23 | 2022-2023 | |
| Celgene Corporation | $40.74 | 2020 | |
| Sk Life Science, INC. | $32.54 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.83 | 2023 | Emgality |
| Acadia Pharmaceuticals INC | $14.10 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dewberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.